Download the appMore options
PisaczekSearch
文AEN-US
Public health and WHOStudies updated this month

Who chooses your treatment? The benefits of medicines are sometimes exaggerated!

Sources: 17 · Article: 19 037 characters ↓

What do Natural Therapy Specialists write?

Stowarzyszenie STOP NOP

The industry influences research, health policy, guidelines, medical practice, and patient decisions.

„Results: We presented a large body of consistent evidence showing that the industry has established means of intervention at every stage of decision-making processes in medical research, strategy, investment, healthcare practice, and education.”Wyniki: Przedstawiliśmy wiele spójnych dowodów wykazujących fakt utworzenia przez przemysł środków interwencji na wszystkich etapach procesów decydujących w zakresie badań medycznych, strategii, nakładów, praktyki i edukacji w zakresie ochrony zdrowia.
Stowarzyszenie STOP NOP

The industry influences both staff training and the decisions made by staff and patients.

„Conclusion: To serve its own interests, the medical industry skillfully influences the production and synthesis of evidence, the understanding of harms, cost estimates, clinical guidelines, and training for healthcare professionals. It also directly influences decisions made by healthcare professionals and consumers.”Wniosek By móc służyć swoim interesom, przemysł medyczny mistrzowsko wpływa na produkcję podstaw dowodowych, syntezę dowodów, rozumienie kwestii szkodliwości, szacunek kosztów, wytyczne kliniczne i szkolenia dla pracowników służby zdrowia, jak również wywiera bezpośredni wpływ na decyzje podejmowane przez pracowników i klientów opieki zdrowotnej.
Stowarzyszenie STOP NOP

The benefits of medicines are sometimes exaggerated and possible harms downplayed, leading to biased guidelines and decisions.

„As a result of these interventions, the benefits of medicines and other products are often exaggerated relative to their possible harms, which are downplayed. Clinical guidelines, medical practice, and healthcare spending are then shaped by biased decisions.”W wyniku tych ingerencji, korzyści stosowania leków i innych produktów często są wyolbrzymiane w stosunku do możliwej szkodliwości, którą się bagatelizuje, a wytyczne kliniczne, praktyka medyczna i nakłady na opiekę zdrowotną są realizowane w oparciu o stronnicze decyzje.
Jerzy Zięba

Jerzy Zięba describes doctors’ training as focused on new medicines, and universities as dependent on pharmaceutical companies’ money.

„Well, pharmaceutical companies and the sponsors of conferences are mainly interested in promoting new medicines, not new knowledge. There is a great deal of knowledge about natural treatments that are effective, safe, and inexpensive, but… medical universities completely ignore these forms of treatment.”No cóż – firmom farmaceutycznym, fundatorom zjazdów, chodzi głównie o popularyzację nowych leków, a nie nowej wiedzy. Wiedza na temat naturalnych środków terapeutycznych, skutecznych, bezpiecznych i tanich, jest ogromna, ale… uczelnie medyczne ignorują całkowicie te formy leczenia.
Jerzy Zięba

Jerzy Zięba asks whether the new minister will resist pressure from the industry. He also describes company representatives visiting pharmacies, where they can review data on prescriptions.

„What can we call the fact that a representative of a pharmaceutical company can enter a pharmacy and review, with complete impunity, all the data about which medicines each doctor prescribes or does not prescribe? The pharmaceutical industry recently published a list of whom it bribes, after all.”Jak można nazwać fakt, że przedstawiciel firmy farmaceutycznej może wejść do apteki i zupełnie bezkarnie przeglądać wszystkie dane dotyczące tego, który lekarz, jakie leki przepisuje lub też jakich nie przepisuje? Przemysł farmaceutyczny przecież niedawno opublikował komu daje łapówki.
Jerzy Zięba

Jerzy Zięba believes that the media’s dependence on pharmaceutical company advertising makes it difficult to publish critical information about their actions.

„That is why it is difficult to find the truth in these kinds of mass media: dependence on the pharmaceutical industry means that publishing the truth does not pay. I once wrote about something that happened to me personally. I approached one of the publishers of what is called a…”Stąd właśnie w tego typu środkach masowego przekazu trudno jest doczytać się prawdy, bo uzależnienie od przemysły farmaceutycznego powoduje, że publikowanie prawdy się nie opłaca. Kiedyś napisałem o przypadku, jaki dotknął mnie osobiście. Zwróciłem się do jednego z wydawców tzw.
Jerzy Zięba

Jerzy Zięba says a publisher may decide not to publish something in order to maintain good relations with advertisers and medical authorities.

„The truth that should be written cannot be published because the publisher cares more about maintaining excellent relations with medical authorities and advertisers than about the reader’s health. In this context, Polish medicine has reached a very dangerous turning point.”Prawda, którą należałoby napisać, nie może być opublikowana, bo wydawnictwo bardziej niż o zdrowie czytelnika dba o nienaganne relacje z autorytetami medycznymi oraz reklamodawcami. W tym kontekście polska medycyna znalazła się na bardzo niebezpiecznym zakręcie.
Jerzy Zięba

Jerzy Zięba claims that the number of vaccinations is planned to keep increasing and that the same doses of medicines are to be used for all patients.

„There are plans to keep increasing the number of vaccinations, and absurd regulations are being introduced that lead to treating diseases rather than patients (for example, using the same doses of medicines for all patients). But what pains me most is that medical and government circles completely downplay the need to promote and strengthen preventive healthcare.”Planuje się ciągłe zwiększanie liczby szczepień, wprowadza absurdalne przepisy powodujące leczenie chorób, a nie pacjentów (np. zunifikowane dla wszystkich chorych dawki leków). Ale dla mnie najboleśniejsze jest to, że kręgi medyczne i rządowe całkowicie bagatelizują konieczność popularyzowania i umacniania profilaktyki zdrowotnej.
Jerzy Zięba

Jerzy Zięba emphasizes that clinical trial procedures are intended to protect patients from the harmful effects of introducing medicines.

„This method of conducting clinical trials was developed to protect future patients from a health disaster. In other words, introducing a medicine for sale without conducting such trials may lead to tragic consequences.”Ten sposób przeprowadzania badań klinicznych został stworzony po to, aby ustrzec przyszłych pacjentów przed zdrowotną katastrofą. Inaczej mówiąc, wprowadzenie leku do obrotu bez przeprowadzenia takich badań może doprowadzić do tragicznych konsekwencji.
Jerzy Zięba

Jerzy Zięba questions whether vaccine clinical trials meet the standards he considers necessary.

„It is well known that no vaccine has ever gone through clinical trials that meet these standards! Not one! Introducing any substance classified as a medicine in Poland, if it had not undergone any clinical tests, however small, would certainly be illegal.”Wiadomo, że żadna szczepionka nigdy nie przeszła przez badania kliniczne spełniające te standardy! Żadna! Wprowadzenie do obrotu w Polsce jakiejkolwiek substancji zaklasyfikowanej jako lek, który nie przeszedł przez jakiekolwiek, najmniejsze nawet testy kliniczne, z pewnością byłoby nielegalne.
Stowarzyszenie STOP NOP

The STOP NOP Association says that industry-sponsored research is used to develop medicines and vaccines and to train staff.

„This is very worrying, given that all this research (sponsored by industry) is used to develop medicines/vaccines supposedly intended to help people, train medical staff, educate medical students, and so on.”Jest to bardzo niepokojące, biorąc pod uwagę fakt, że wszystkie te badania (sponsorowane przez przemysł) są wykorzystywane do tworzenia leków / szczepionek mających rzekomo na celu pomóc ludziom, szkolenia personelu medycznego, edukowania studentów medycyny itd.
Henryk Różański

Henryk Różański describes companies’ efforts to remove natural products that compete with their products from the market.

„If, for example, a corporation decides to introduce lily of the valley as an encapsulated extract, or as a synthetic cardiac alternative, it does everything it can to remove dried lily-of-the-valley leaves from the market. That is their natural instinct.”Jeśli np. koncern postanowi wprowadzić konwalię w postaci ekstraktu kapsułkowanego, albo alternatywy syntetycznej nasercowej robi wszystko, żeby doprowadzić do usunięcia z rynku surowca w postaci suszonych liści konwalii. Jest to ich naturalny odruch.
Hubert Czerniak

Hubert Czerniak presents the sale of cancer medicines as a business in which profit may take precedence over lasting cures.

„Will corporate bigwigs take effective action against cancer? Why would they? After all, it is better to keep treating people than to cure them permanently. The numbers have to add up. And how does that fit with the motto of all doctors: Primum non nocere (First, do no harm)?”Czy korporacyjne tuzy podejmą skuteczną walkę z rakiem? Po co mieliby to robić? Przecież lepiej jest leczyć, aby leczyć, niż trwale wyleczyć. Pieniądze muszą się zgadzać. A jak to się ma do hasła wszystkich lekarzy: Primum non nocere (Po pierwsze nie szkodzić)?
Jerzy Zięba

Jerzy Zięba acknowledges that academic medicine and the pharmaceutical industry effectively save lives in emergencies.

„We must not forget these tremendously commendable achievements. When we have an accident, break a leg, suffer a heart attack or stroke, or have any other acute health problem, academic medicine and the pharmaceutical industry save lives very effectively.”O tych niezwykle chwalebnych sukcesach nie wolno nam zapominać. Wtedy, kiedy ulegniemy wypadkowi, złamiemy nogę, mamy zawał serca, udar mózgu czy jakikolwiek inny problem zdrowotny typu ostrego, medycyna akademicka i przemysł farmaceutyczny w sposób niezwykle efektywny ratują życie.
Jerzy Zięba

Jerzy Zięba emphasizes that academic medicine and the pharmaceutical industry effectively save lives in cases of sudden health problems.

„We must not forget these tremendously commendable achievements. When we have an accident, break a leg, suffer a heart attack or stroke, or have any other acute health problem, academic medicine and the pharmaceutical industry save lives very effectively.”O tych niezwykle chwalebnych sukcesach nie wolno nam zapominać. Kiedy ulegniemy wypadkowi, złamiemy nogę, mamy zawał serca, udar mózgu czy jakikolwiek inny problem zdrowotny typu ostrego, medycyna akademicka i przemysł farmaceutyczny w sposób niezwykle efektywny ratują życie.

What does scientific research from PubMed · Europe PMC say?

We selected 6 studies with the best, positive results. This is a selection, not a full review of all research.

Total number of studies on this topic in PubMed: 1 282.

Aim of the study: The relationship between physicians and the pharmaceutical industry has evolved significantly over the years, raising concerns about ethical practices in medical prescribing. This article explores the multifaceted influence of pharmaceutical companies on physician behaviour, highlighting how marketing strategies, financial incentives, and promotional activities can compromise the integrity of clinical decision-making.

Results: This article explores the multifaceted influence of pharmaceutical companies on physician behaviour, highlighting how marketing strategies, financial incentives, and promotional activities can compromise the integrity of clinical decision-making. Through a comprehensive review of the literature, the article examines the implications of inculcating ethics in undergraduate medical programmes, so future healthcare professionals understand the importance of making evidence-based decisions. Furthermore, this article calls for a critical evaluation of existing regulatory frameworks and advocates for stronger ethical guidelines to ensure that physician prescriptions are based solely on patient needs rather than external pressures from the pharmaceutical industry. Ultimately, it emphasizes the importance of restoring ethical standards in medicine to safeguard patient welfare and maintain the sanctity of the physician-patient relationship.

Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: To increase nurse practitioners' (NPs) awareness of the conflict of interest that exists between the NPs' primary goal of making the best medication choices for patients and the potentially negative impact that the pharmaceutical industry's marketing strategies have on these choices.

Results: Healthcare professionals are given gifts, dinners, and other inducements in the drug industry's effort to increase consumerism and drug sales. The current method of drug promotion increases sales but also increases healthcare expenses. Research also indicates that the pharmaceutical marketing strategies influence the judgments that NPs and other healthcare professionals make about patient care and drug prescriptions.

Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a foundation for the delivery of quality cardiovascular care.

Results: Hyperlinked references are provided for each modular knowledge chunk to facilitate quick access and review. More structured guidelines–including word limits (“targets”) and a web guideline supplement for useful but noncritical tables and figures–are 2 such changes. This Preamble is an abbreviated version, with the detailed version available online. The reader is encouraged to consult the full-text guideline for additional guidance and details, since the executive summary contains mainly the recommendations.

Money for the studygovernment, public institutions · NIGMS NIH HHS
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studyreview of many studies

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: Clinical trials are increasingly supported by industries while previous studies have shown that industry-supported studies have more favorable results than studies with other sources of funding. In the present study, we investigated the association of industrial funding on the results of clinical trials regarding chemotherapy in prostate cancer.

Results: In this study, out of the 91 studies, 80.2% were funded by pharmaceutical companies and 19.8% were funded by government agencies. The end result of 61.6% of the studies funded by pharmaceutical companies was an increase in survival due to chemotherapy, whereas only 27.8% of the studies sponsored by government agencies reported positive results (P-value=0.010). In fact, industry-funded trials more often presented statistically significant positive results for survival (OR: 4.17; CI, 1.34-12.99). In general, there was no significant difference in the degree of bias between the two groups. According to this study, despite of the similar quality of studies funded by pharmaceutical companies and government agencies, positive results were more common in studies related to pharmaceutical companies. Therefore, this point should be taken into account when making a decision on the best treatment approach.

Money for the studygovernment, public institutions · National Institutes of Health, Iran University of Medical Sciences
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studyreview of many studies

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: This study aimed to examine multi-stakeholder perceptions regarding the integration of patient input and patient preference information (PPI) across the medical product lifecycle and to identify priority areas and regulatory prerequisites for its effective incorporation in South Korea.

Results: Among 183 respondents, perceived necessity of incorporating patient input was high, whereas current incorporation was rated substantially lower, indicating a clear gap between stakeholder expectations and current practice (p < 0.001). On average across lifecycle stages, respondents from patient organizations reported higher perceived necessity (4.20) than respondents from pharmaceutical (3.39; p < 0.001) and medical device companies (3.62; p = 0.004). Across priority areas, necessity ratings were highest for products requiring direct patient use (4.14) and lowest for contexts involving uncertainty in efficacy or safety (3.42). For uncertainty in efficacy or safety, the medical device company group reported significantly higher ratings than the pharmaceutical company group (3.61 vs 2.91; p = 0.029).

Money for the studygovernment, public institutions · Ministry of Food and Drug Safety
Do the authors have ties to companies?no — the authors say so
Did a manufacturer help with the study?NO
Type of studyobservation of people
Participants183

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: Exposure-response (ER) analyses assessing the efficacy of large molecule therapeutics are often susceptible to confounding, where associations between drug exposure and patient disease severity can obscure true ER signals and complicate dose selection.

Results: In contrast, the use of advanced statistical methods for causal inference is inconsistent (45.6% usage), and confidence in their reliability is mixed, with 32.8% of respondents expressing uncertainty and most others rating them only moderate or somewhat reliable. While the majority agreed that confounded ER analyses should be interpreted with caution (79.2%), opinions diverged regarding their value in decision-making when dose-ranging data is insufficient. This uncertainty, coupled with a recognized need for additional alignment with health authorities, led to a call for best-practice guidance (92.8% view as valuable). Overall, the survey findings highlight a need for an industry-wide common approach and the development of clear frameworks to manage and interpret ER confounding for large molecule therapeutics.

Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studyobservation of people
Participants125

“Not stated” does not mean nobody paid — the database does not always record it.

What do orthomolecular medicine doctors write?

Orthomolecular Medicine News Service
„This resulted in the FDA increasingly making decisions favorable to the medical-pharmaceutical industry, supporting that industry's self-serving "disease care" interests [1,9]. From its inception, the overriding interest of organized medicine has been to generate profits and to assure its monopoly status in healthcare Over the last 100 years, medicine has had a history of ostracizing relevant competitors who encroach on the profits in its bottom line [13-15]. Throughout much of that history, the FDA has been a willing assistant and enforcer of the medical profession's profit interests [1,12,16].”This resulted in the FDA increasingly making decisions favorable to the medical-pharmaceutical industry, supporting that industry's self-serving "disease care" interests [1,9]. From its inception, the overriding interest of organized medicine has been to generate profits and to assure its monopoly status in healthcare Over the last 100 years, medicine has had a history of ostracizing relevant competitors who encroach on the profits in its bottom line [13-15]. Throughout much of that history, the FDA has been a willing assistant and enforcer of the medical profession's profit interests [1,12,16].
Orthomolecular Medicine News Service
„FDA Guidance for Industry: Frequently Asked Questions about Medical Foods. Juven(c) Support Wound Healing. Passwater RA (2010) "New FDA Qualified Health Claims for Selenium: An interview with Dr. Gerhard Schrauzer". Whole Foods Magazine. October 2010. Passwater RA (2009) "Why the FDA is confused about selenium". Whole Foods Magazine. November 2009. Tips SC (2022) "This may be the Supreme Court's Most Important Decision This Year: West Virginia v. EPA". Whole Foods Magazine. September 2022. Best M, Neuhauser D (2004) Ignaz Semmelweis and the birth of infection control. Qual Saf Health Care 13:233-234.”FDA Guidance for Industry: Frequently Asked Questions about Medical Foods. Juven(c) Support Wound Healing. Passwater RA (2010) "New FDA Qualified Health Claims for Selenium: An interview with Dr. Gerhard Schrauzer". Whole Foods Magazine. October 2010. Passwater RA (2009) "Why the FDA is confused about selenium". Whole Foods Magazine. November 2009. Tips SC (2022) "This may be the Supreme Court's Most Important Decision This Year: West Virginia v. EPA". Whole Foods Magazine. September 2022. Best M, Neuhauser D (2004) Ignaz Semmelweis and the birth of infection control. Qual Saf Health Care 13:233-234.
Orthomolecular Medicine News Service
„A systematic review found over half of guideline authors had industry ties, particularly in areas where pharmaceuticals dominate treatment(50,51). Many guideline panels lack formal processes for declaring conflicts of interest, with only 2 out of 44 reviewed guidelines containing specific disclosures(47). Undisclosed financial relationships were identified in 24% of authors who claimed no conflicts and 70% of guidelines(52). Impact on Care: Industry ties may influence guideline recommendations, potentially leading to overdiagnosis and overtreatment(53,54).”A systematic review found over half of guideline authors had industry ties, particularly in areas where pharmaceuticals dominate treatment(50,51). Many guideline panels lack formal processes for declaring conflicts of interest, with only 2 out of 44 reviewed guidelines containing specific disclosures(47). Undisclosed financial relationships were identified in 24% of authors who claimed no conflicts and 70% of guidelines(52). Impact on Care: Industry ties may influence guideline recommendations, potentially leading to overdiagnosis and overtreatment(53,54).

Sources (17)

Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.